Company intelligence / Profile preview
Partner Therapeutics
Lexington, Massachusetts, United Statespartnertx.com ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Commercial
01
Overview
Partner Therapeutics has a commercial product Leukine (sargramostim), which is FDA-approved for treatment of acute myelogenous leukemia (AML) in older patients and for use in both allogeneic and autologous bone marrow transplantation. The company is conducting clinical trials for additional indications including sepsis, melanoma, and COVID-19[4][5].
- Therapeutic areas
- ImmunologyOncologyRare DiseasesNeurologyInfectious Diseases
- Modalities
- Recombinant proteinsimmunostimulants
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Merus N.V.Biomedical Advanced Research and Development Authority (BARDA)Tanner Pharma GroupECOG-ACRINNobelpharma Co. Ltd.University of Colorado
Beyond the preview
Go deeper on Partner Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Partner Therapeutics.